Alps Electric and PICC made strategic investments as part of a round that boosted the total raised by Neusoft's medical services spinout to more than $230m.

Precision medicine developer Metabolon has now raised $80m since 2000, and its earlier investors include Sumitomo and Syngenta.

A round up of all the latest news on www.globalcorporateventuring.com for our subscribers.

Johnson & Johnson, Eli Lilly and Pharmstandard exited the IBD treatment developer through an initial public offering that could eventually reach $103m in size.

The pharmaceutical company has boosted its stake in mRNA drug developer and strategic partner Moderna to 9%, lifting Moderna's overall funding to at least $790m.

The healthcare concierge service has added $70m to the $22.5m it raised from corporates McKesson and Independence Health last year.

Johnson & Johnson led the $93m, two-tranche equity portion, which also included GlaxoSmithKline fund Action Potential Venture Capital.

Eze Vidra, who helped GV set up its aborted European branch, has taken the chief innovation officer role at clinical trial connection platform TrialReach.

Lundbeck-backed Iconic Therapeutics, which aims to apply tissue factor biology to retinal disease and cancer treatments, has now raised $80m altogether.